FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583669203> ?p ?o ?g. }

• W2583669203 endingPage "205031211769040" @default.
• W2583669203 startingPage "205031211769040" @default.
• W2583669203 abstract "Adverse drug reactions can cause increased morbidity and mortality, and therefore information needs to be studied systematically. Little is known about the adverse drug reactions for chronic obstructive pulmonary disease therapy. The goal of this study is to assess the expectedness, seriousness and severity of adverse drug reactions during chronic obstructive pulmonary disease therapy based on their reporting in the national pharmacovigilance system.This was a prospective, observational, 1-year, real-life study about the pharmacotherapy of a sample of 390 chronic obstructive pulmonary disease patients. Prescribed medicines were systematized and national pharmacovigilance databases were searched for reported adverse drug reactions. The expectedness was evaluated through the review of the summary of product characteristics, the seriousness was evaluated by the clinicians based on the life threatening nature of the adverse drug reactions, and the severity was evaluated through Hartwig's Severity Assessment Scale. Descriptive statistics of the reported adverse drug reactions was performed and the relative risk of developing an adverse drug reaction with all international non-proprietary names included in the analysis was calculated.Results confirm that the chronic obstructive pulmonary disease is a disease with high appearance of adverse drug reactions, and causes many additional costs to the healthcare system. Unexpected and severe adverse drug reactions are frequent. A total of 4.8% of adverse drug reactions were evaluated as life threatening. Majority of adverse drug reactions are classified in Levels 1 (32.6%), 2 (26.4%) and 3 (19%) according to Hartwig's Severity Assessment Scale. Approximately 22% of reported adverse drug reactions affect people's everyday life to a greater extent and require additional therapy which might further increase the risk. The relative risk of developing an adverse drug reaction was highest for novphyllin (relative risk = 0.65), followed by aclidinium bromide (relative risk = 0.09). Both indacaterol and salbutamol are with a relative risk of 0.07.In conclusion, the medicines for chronic obstructive pulmonary disease cause many serious adverse drug reactions, most of them were unexpected, lacking in the short product characteristics. Appropriate reporting of adverse drug reactions is necessary to decrease the risk of patients and healthcare system." @default.
• W2583669203 created "2017-02-10" @default.
• W2583669203 creator A5004728387 @default.
• W2583669203 creator A5015085872 @default.
• W2583669203 creator A5017418790 @default.
• W2583669203 creator A5024117953 @default.
• W2583669203 creator A5048973262 @default.
• W2583669203 creator A5050863807 @default.
• W2583669203 date "2017-01-31" @default.
• W2583669203 modified "2023-09-23" @default.
• W2583669203 title "Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy" @default.
• W2583669203 cites W1608937346 @default.
• W2583669203 cites W1765287762 @default.
• W2583669203 cites W1963559208 @default.
• W2583669203 cites W1969879564 @default.
• W2583669203 cites W1970269457 @default.
• W2583669203 cites W1985630117 @default.
• W2583669203 cites W1990788472 @default.
• W2583669203 cites W1995635839 @default.
• W2583669203 cites W2034497364 @default.
• W2583669203 cites W2038757044 @default.
• W2583669203 cites W2067978628 @default.
• W2583669203 cites W2078531432 @default.
• W2583669203 cites W2107845357 @default.
• W2583669203 cites W2119463649 @default.
• W2583669203 cites W2146518565 @default.
• W2583669203 cites W2153972688 @default.
• W2583669203 cites W2277284030 @default.
• W2583669203 cites W2348528624 @default.
• W2583669203 cites W2410676106 @default.
• W2583669203 doi "https://doi.org/10.1177/2050312117690404" @default.
• W2583669203 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5308439" @default.
• W2583669203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28228952" @default.
• W2583669203 hasPublicationYear "2017" @default.
• W2583669203 type Work @default.
• W2583669203 sameAs 2583669203 @default.
• W2583669203 citedByCount "14" @default.
• W2583669203 countsByYear W25836692032020 @default.
• W2583669203 countsByYear W25836692032021 @default.
• W2583669203 countsByYear W25836692032022 @default.
• W2583669203 countsByYear W25836692032023 @default.
• W2583669203 crossrefType "journal-article" @default.
• W2583669203 hasAuthorship W2583669203A5004728387 @default.
• W2583669203 hasAuthorship W2583669203A5015085872 @default.
• W2583669203 hasAuthorship W2583669203A5017418790 @default.
• W2583669203 hasAuthorship W2583669203A5024117953 @default.
• W2583669203 hasAuthorship W2583669203A5048973262 @default.
• W2583669203 hasAuthorship W2583669203A5050863807 @default.
• W2583669203 hasBestOaLocation W25836692031 @default.
• W2583669203 hasConcept C126322002 @default.
• W2583669203 hasConcept C17744445 @default.
• W2583669203 hasConcept C177713679 @default.
• W2583669203 hasConcept C197934379 @default.
• W2583669203 hasConcept C199539241 @default.
• W2583669203 hasConcept C23131810 @default.
• W2583669203 hasConcept C2776650110 @default.
• W2583669203 hasConcept C2779134260 @default.
• W2583669203 hasConcept C2780035454 @default.
• W2583669203 hasConcept C2780542314 @default.
• W2583669203 hasConcept C500440147 @default.
• W2583669203 hasConcept C57658597 @default.
• W2583669203 hasConcept C71924100 @default.
• W2583669203 hasConcept C98274493 @default.
• W2583669203 hasConceptScore W2583669203C126322002 @default.
• W2583669203 hasConceptScore W2583669203C17744445 @default.
• W2583669203 hasConceptScore W2583669203C177713679 @default.
• W2583669203 hasConceptScore W2583669203C197934379 @default.
• W2583669203 hasConceptScore W2583669203C199539241 @default.
• W2583669203 hasConceptScore W2583669203C23131810 @default.
• W2583669203 hasConceptScore W2583669203C2776650110 @default.
• W2583669203 hasConceptScore W2583669203C2779134260 @default.
• W2583669203 hasConceptScore W2583669203C2780035454 @default.
• W2583669203 hasConceptScore W2583669203C2780542314 @default.
• W2583669203 hasConceptScore W2583669203C500440147 @default.
• W2583669203 hasConceptScore W2583669203C57658597 @default.
• W2583669203 hasConceptScore W2583669203C71924100 @default.
• W2583669203 hasConceptScore W2583669203C98274493 @default.
• W2583669203 hasLocation W25836692031 @default.
• W2583669203 hasLocation W25836692032 @default.
• W2583669203 hasLocation W25836692033 @default.
• W2583669203 hasLocation W25836692034 @default.
• W2583669203 hasLocation W25836692035 @default.
• W2583669203 hasOpenAccess W2583669203 @default.
• W2583669203 hasPrimaryLocation W25836692031 @default.
• W2583669203 hasRelatedWork W2289010737 @default.
• W2583669203 hasRelatedWork W2412428663 @default.
• W2583669203 hasRelatedWork W2583669203 @default.
• W2583669203 hasRelatedWork W3110215111 @default.
• W2583669203 hasRelatedWork W3113386111 @default.
• W2583669203 hasRelatedWork W4229455185 @default.
• W2583669203 hasRelatedWork W4282585499 @default.
• W2583669203 hasRelatedWork W4298082289 @default.
• W2583669203 hasRelatedWork W56637561 @default.
• W2583669203 hasRelatedWork W2186394847 @default.
• W2583669203 hasVolume "5" @default.
• W2583669203 isParatext "false" @default.
• W2583669203 isRetracted "false" @default.
• W2583669203 magId "2583669203" @default.

• next